Skip to main content
Aker BioMarine logo

Aker BioMarine — Investor Relations & Filings

Ticker · AKBM ISIN · NO0010886625 LEI · 549300V34T6VWDSYWE64 OL Agriculture, forestry and fishing
Open in API
Filings indexed 508 across all filing types
Latest filing 2026-02-12 Earnings Release
Country NO Norway
Listing OL AKBM

About Aker BioMarine

https://www.akerbiomarine.com/

Aker BioMarine is a biotechnology innovator that sustainably harvests Antarctic krill to develop and supply krill-derived ingredients. The company's core business focuses on producing ingredients for the human health and nutrition markets, including nutraceuticals and dietary supplements. It also serves the aquaculture and animal feed sectors with specialized products. Aker BioMarine leverages its vertically integrated supply chain and scientific research to create a portfolio of products that extends to agricultural biostimulants and pharmaceutical applications. The company is committed to sustainable operations and the scientific validation of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Fourth quarter 2025 results for Aker BioMarine
Earnings Release Classification · 98% confidence The document provides a summary of financial highlights, segment performance, and outlook for the fourth quarter of 2025. While it contains financial data, it is a short announcement (under 5,000 characters) that explicitly states 'Attached is the quarterly presentation for Q4' and provides links to external files and a webcast. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the full financial report itself. Q4 2025
2026-02-12 English
MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - Attachment: Skjema for melding om transaksjoner utført av personer med ledelsesansvar («primærinnsidere») og deres nærstående (KRT-1500) (17).pdf
Director's Dealing Classification · 100% confidence The document is a KRT-1500 form, which is the standard regulatory filing in Norway for reporting transactions by persons discharging managerial responsibilities (PDMRs) and their closely associated persons. This corresponds directly to the 'Director's Dealing' category, as it details a share purchase by a company director/manager.
2025-11-05 Norwegian
MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER
Director's Dealing Classification · 100% confidence The document is a mandatory notification of a share purchase by a primary insider (a Board Director). It explicitly mentions the purchase of 551 shares and the resulting total holdings. This falls directly under the definition of 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2025-11-05 English
MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - Attachment: Skjema for melding om transaksjoner utført av personer med ledelsesansvar («primærinnsidere») og deres nærstående (KRT-1500) (15).pdf
Director's Dealing Classification · 100% confidence The document is a KRT-1500 form, which is the standard Norwegian regulatory form for reporting transactions by persons discharging managerial responsibilities (PDMRs) and their closely associated persons. The content explicitly details a share purchase by a primary insider (Trond Atle Smedsrud) of Aker BioMarine ASA, including the ISIN, transaction type (purchase), price, volume, and date. This falls directly under the definition of 'Director's Dealing'.
2025-11-05 Norwegian
MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER
Director's Dealing Classification · 100% confidence The document is a mandatory notification of a share purchase by a primary insider (CEO of Emerging Businesses). It explicitly mentions the purchase of 6500 shares by Trond Atle Smedsrud and references the Market Abuse Regulation (MAR) requirements for insider notifications. This fits the definition of a Director's Dealing (DIRS) filing.
2025-11-05 English
Third quarter 2025 results for Aker BioMarine - Attachment: Aker BioMarine Q3 2025 Presentation publish.pdf
Investor Presentation Classification · 100% confidence The document is a detailed quarterly financial presentation for Q3 2025. It contains financial highlights, segment performance analysis (Human Health, Consumer Health, Emerging Business), a profit and loss statement, balance sheet, cash flow analysis, and strategic value creation plans. It is clearly a comprehensive report on quarterly performance rather than just an earnings release (which would be shorter and focused on highlights) or a transcript. Given the depth of the financial data and the presentation format, it is classified as an Interim/Quarterly Report.
2025-10-31 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.